Jazz Pharmaceuticals Announces First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Jazz Pharmaceuticals (JAZZ) PT Raised to $201 at BMO Capital
May 9, 2018 6:45 AM EDTBMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $201.00 (from $199.00) while maintaining an Outperform rating.
Analyst Gary Nachman commented, "JAZZ reported 1Q revenue of $445mm vs. BMO/consensus $433mm/$434mm and adj. EPS of $2.98 vs. BMO/consensus $2.74/$2.77. The... More
Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 21c
May 8, 2018 4:34 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.98, $0.21 better than the analyst estimate of $2.77. Revenue for the quarter came in at $444.61 million versus the consensus estimate of $434.87 million.
"The first quarter was highlighted by strong revenue growth, cash flow generation and execution across... More
